UNSPSC 51434933: Guanethidine/hydrochlorothiazide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434933 Guanethidine/hydrochlorothiazide is a Commodity code that in practice does not map to meaningful recent state and local procurement activity. The code's nominal scope is a specific antihypertensive drug combination, yet the three recent opportunities tagged under it involve broader pharmaceutical and medication procurement — advanced life support medications for emergency medical services, direct-to-manufacturer prescription program design, and generic multi-source pharmaceuticals distributed through cooperative purchasing — none of which are centered on guanethidine/hydrochlorothiazide specifically. State and local buying under this code tier does not surface in current solicitations.

The mismatch between the code's specificity and the solicitations' actual scope suggests either systematic miscoding or that the code sits beneath active parent-level pharmaceutical-procurement categories where state and local agencies are pursuing broader drug-supply, emergency-response medication, and cooperative-purchasing arrangements. The City of Tampa's April 2026 IFB for Advanced Life Support Medications (Bid 26P00188, due April 8, 2026) illustrates the type of work: acquisition of specific formulations (Labetalol, Epinephrine, Adenosine, Diltiazem vials) for Tampa Fire Rescue at an estimated contract value of $40,000.00 with a Small Local Business Enterprise set-aside option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP (S1070000015802, due March 26, 2026) sought generic multi-source pharmaceuticals and OTC products through three authorized wholesalers across state and local facilities in Minnesota and Oregon, with contract terms of two years and optional extensions. For business development purposes, pursue this code's parent-tier pharmaceutical and medical-supply families to identify actionable opportunities; the Commodity code itself shows no direct buying signals.